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IL-12– and IL-23–induced T helper cell subsets: 
birds of the same feather ﬂock together
 
Estelle Bettelli and Vijay K. Kuchroo
 
Traditionally, CD4
 
 
 
 T cells have been separated into two different subsets 
named T helper (Th)1 and Th2. A new IL-23–driven subset of Th cells called 
Th
 
IL-17
 
 has now been described. The data suggest that IL-23 plays an important 
role in the differentiation of autoreactive pathogenic T cells. Whether these 
IL-23–induced Th
 
IL-17
 
 cells are a unique subset or are related to other Th 
subsets is discussed.
 
Th1 and Th2 subsets can be distin-
guished by their cytokine profiles and
effector functions. Th1 cells produce
IFN-
 
 
 
, IL-2, and lymphotoxin, and
mediate delayed type hypersensitivity
responses and macrophage activation,
whereas Th2 cells secrete IL-4, IL-5,
IL-10, and IL-13, and contribute to
eosinophilic inflammation and allergic
reactions (1, 2). IFN-
 
 
 
 and IL-4 antag-
onize each other and cross-regulate the
expansion and functions of Th1 and
Th2 cells.
Over the years, considerable effort
has been devoted to the identification
of cell surface antigens and transcrip-
tion factors that are unique to Th1 and
Th2 cell subsets. Th1 cells preferentially
express the IL-12R
 
 
 
2 chain, IL-18 re-
ceptor, P-selectin glycoprotein ligand-1,
Chandra, and the CXCR3 and CXCR5
chemokine receptors (1). Th2 cells ex-
press the chemokine receptors CCR3,
CCR5, and CCR8, and inducible co-
stimulatory molecule (ICOS) (1). We
have recently identified T cell immu-
noglobulin and mucin containing mol-
ecule-3, a cell surface molecule that is
differentially expressed on the surface
of terminally differentiated Th1 cells
(3). The preferential expression of these
cell markers is probably a consequence
of the cytokines and transcription factors
that promote differentiation of these T
cell subsets.
Distinct signaling pathways govern
the differentiation of Th1 versus Th2
cells. IL-12 and IFN-
 
 
 
 signals are im-
portant for Th1 cell differentiation.
The Th1 cytokine IFN-
 
 
 
 signals through
signal transducer of activated T cells
(STAT-1) which in turn activates
the T-box transcription factor T-bet,
which is the key inducer of IFN-
 
 
 
 and
Th1 cell differentiation (1, 2). The effects
of T-bet are so potent that expression of
this transcription factor in previously
differentiated Th2 cells reverses their
phenotype and results in IFN-
 
 
 
 pro-
duction (4). T-bet appears to act before
IL-12 signaling in Th1 cell develop-
ment, but IL-12–mediated activation
of STAT-4 appears to be essential for
the stabilization of IFN-
 
 
 
 production
and the development of terminally differ-
entiated Th1 cells (1, 2). IL-4 induces
STAT-6 activation, which promotes
the expression of GATA-3, an essential
transcription factor for both IL-4 pro-
duction and for the development of
Th2 cells (1, 2).
 
A new Th cell subset?
 
Recently, IL-23 was identified as a
new member of the IL-12 family of cy-
tokines (5). IL-23 is a heterodimeric
cytokine that comprises the p40 subunit
of IL-12 and a specific p19 subunit. The
p40–p19 complex is secreted by acti-
vated DCs and macrophages (5). In this
issue, Langrish et al. (page 233) de-
scribe a subset of CD4
 
 
 
 T cells that
they call Th
 
IL-17
 
 cells, which are gener-
ated by isolating T cells from experi-
mental autoimmune encephalomyelitis
(EAE)-susceptible SJL mice immunized
with an encephalitogenic peptide and
culturing them with IL-23 (6). The au-
thors consider this a unique Th subset
since these T cells, in contrast to Th1
cells, produce IL-17, IL-17F, IL-6,
TNF, and low levels of IFN-
 
 
 
. These
experiments confirm earlier observa-
tions by Aggarwal et al. (7), showing
that IL-23 could induce T cells that se-
crete IL-17, no IL-4, and little IFN-
 
 
 
.
Both studies suggested that these Th
 
IL-17
 
cells represent a subset of Th cells distinct
from Th1 and Th2 cells (7). It should
be noted, however, that IL-23–induced
Th
 
IL-17
 
 cells continue to produce low
levels of IFN-
 
 
 
, a hallmark cytokine of
Th1 subset.
Although the known cytokine pro-
file of Th
 
IL-17
 
 cells distinguishes them
from previously described Th1 and Th2
cells, their origin remains unclear, and
the possibility that they arise from early
Th1 or Th2 cells needs to be considered.
The work by Langrish et al. (6) and from
other groups (7, 8) shows that IL-23R is
expressed only on activated and memory
cells and that IL-23 does not act on naive
T cells to induce Th cell differentiation.
In addition, Langrish et al. could detect
little or no IL-17–producing cells after
primary stimulation of naive TCR trans-
genic T cells in the presence of IL-23.
Therefore, it is unlikely that Th
 
IL-17
 
 cells
emerge from a unique precursor con-
tained in the pool of naive T cells.
Rather, IL-17–producing Th cells could
emerge from previously activated Th
cells. It is therefore interesting to specu-
late whether the Th
 
IL-17
 
 subset arises
from early activated Th1 or Th2 cells
before they are terminally differentiated
into effector cells by IL-12 or IL-4, re-
spectively (Fig. 1).
 
Th subsets in autoimmunity
 
Several studies have supported the no-
tion that Th1 cells that produce proin-
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flammatory cytokines promote the
development of inflammation and
autoimmunity. In mouse models of
autoimmune diseases, such as type 1 di-
abetes and EAE, CD4
 
 
 
 T cells that
produce large amounts of IFN-
 
 
 
 and
little IL-4 induce disease and tissue
destruction upon adoptive transfer (9,
10). Th1 cytokines are present in the
inflammatory EAE lesions in the cen-
tral nervous system, and Th2 cells are
absent, strongly suggesting that Th1
cytokines play a role in the pathogene-
sis of the disease (11, 12). Furthermore,
T cells from resistant B10.S mice could
transfer EAE when activated in the
presence of IL-12 before transfer, sug-
gesting that there is a defect in the gen-
eration of Th1 cells in the resistant
mice and once differentiated to Th1
cells in vitro, the cells can mediate their
effector function and transfer disease
(13, 14). These findings, along with the
observation that Th1 clones with speci-
ficity for myelin antigens can transfer
EAE, strongly suggests that Th1 cells
are crucial for the induction of EAE
(15, 16). But there are several reports
demonstrating that mice deficient for
IFN-
 
 
 
, IFN-
 
 
 
 receptor, or STAT-1
are highly susceptible to EAE, which
calls into question the role of Th1 cells
in inducing disease (15–19). However,
T-bet is essential for the induction of
EAE. T-bet
 
 
 
/
 
 
 
 mice are highly resis-
tant to EAE, and antisense oligonucle-
otides that suppress the induction of
T-bet and IFN-
 
 
 
 completely prevent
development of disease (19, 20).
Langrish et al. show that IL-23–
driven T cells that produce IL-17 are
highly pathogenic in contrast to Th1
cells, which in their hands cannot in-
duce disease (6). Can the new findings
of Langrish et al. help resolve the con-
flicting data regarding the role of Th
cells in EAE?
 
IL-17 in autoimmunity
 
IL-17 is the prototypic member of a
new cytokine family that is involved in
the proliferation, maturation, and che-
motaxis of neutrophils. IL-17 has plei-
tropic activities including the induction
of proinflammatory cytokines TNF,
IL-1, IL-6, IL-8, granulocyte colony–
stimulating factor, and monocyte chemo-
attractant protein (MCP-1) on various
cell types and the promotion of stem
cell factor– and granulocyte colony–
stimulating factor–mediated granu-
lopoiesis. IL-17 also acts on T cells as a
costimulatory factor and enhances al-
lorejection via promotion of DC matu-
ration (21, 22). IL-17 has also been de-
tected in the sera and diseased tissues of
patients with rheumatoid and Lyme ar-
thritis, multiple sclerosis, systemic lupus
erythematous, and asthma, suggesting
its involvement in the development of
various human autoimmune diseases
(21, 22).
Langrish et al. tested whether IL-17
production could contribute directly to
EAE severity by injecting mice with
neutralizing antibodies against IL-17.
Anti–IL-17 antibody treatment resulted
in partial protection from EAE (6).
These results are in accord with previ-
ous results which showed that IL-17–
deficient mice are resistant to the de-
velopment of collagen-induced arthritis
and EAE and suggest a pathogenic role
of IL-17 in EAE (23). However, it is
important to note that in the current
study the anti–IL-17 antibody treat-
ment could only confer partial protec-
tion and that the severe disease ob-
served with the transfer of Th
 
IL-17
 
 cells
could not be blocked by anti–IL-17
antibody treatment. These observations
suggest that either the IL-17 could not
be completely neutralized by the anti-
body or that other factors besides IL-17
are also critical in the pathogenicity of
Th
 
IL-17
 
 cells in EAE.
 
Origin of Th
 
IL-17
 
 cells?
 
The lack of pathogenicity of Th1 cells
in the experiments described by Lan-
grish et al. (6), although surprising, could
explain previous data that showed that
IFN-
 
 
 
 (and potentially Th1 cells) is not
crucial for the induction of disease and
that IFN-
 
 
 
 
 
/
 
 
 
 and IFN-
 
 
 
R
 
 
 
/
 
 
 
 mice
are still susceptible to EAE (15–18). It
is IL-23–driven Th
 
IL-17
 
 cells that are
crucial for inducing EAE! As discussed
by the authors, it is possible that my-
elin-specific IFN-
 
 
 
–producing short-
term T cell lines described previously as
inducers of EAE, contained IL-17–
producing cells that were highly patho-
genic. However, given that IFN-
 
 
 
 and
IL-17 production are almost mutually
exclusive in long-term culture, residual
IL-17 production in fully differentiated
Th1 cells or clones produced in the
presence of IL-12 is unlikely to ac-
count for the previously well-described
pathogenicity of Th1 cells. In addition,
these data do not explain why T-bet–
deficient mice, generated by two dif-
Figure 1. Hypothetical model of ThIL-17 cell development. IL-23–driven THIL-17 cells may represent a 
unique subset of Th cells that arises from a novel Th precursor cell. Alternatively, THIL-17 cells may develop 
from pre–Th1 cells that differentiate into Th1 cells in the presence of IL-12, but THIL-17 cells in the 
presence of IL-23. Dashed arrows indicate hypothetical pathways of ThIL-17 subset development.
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ferent technologies (19, 20), are resis-
tant to the development of EAE.
One possible mechanism to explain
and integrate all these results into a co-
hesive schema is that IL-23 acts on pre-
viously activated, and possibly differ-
entiated, T cells to generate Th
 
IL-17
 
effector T cells. IL-12–driven Th1 cells
and IL-23–driven Th
 
IL-17
 
 cells may be
related and arise from the same T-bet–
expressing precursor, a “pre–Th1 cell”
(Fig. 1). This model would predict that
when T-bet is activated to induce Th1
differentiation, these cells express IL-
12R and IL-23R on their surface. But
depending on the cytokine available in
the milieu they become further differ-
entiated; they become bonafide IFN-
 
 
 
–producing Th1 cells if they come in
contact with IL-12, but become Th
 
IL-17
 
cells if further activated by IL-23. This
model might explain why T-bet (19),
IL-12/IL-23 p40– (24) and IL-23p19–
deficient mice (25) are resistant to EAE
and why IFN-
 
 
 
–, IFN-
 
 
 
R– (14–17),
and IL-12p35–deficient mice (24, 26)
are still susceptible to disease. Based on
this schema, T-bet would play a central
role in the generation of Th1 precur-
sors that can further differentiate into
either Th1 cells, which are crucial for
resistance against intracellular patho-
gens, or Th
 
IL-17
 
 cells, which may be es-
sential for mediating tissue destruction
and inducing autoimmunity.
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